Furiex Pharmaceuticals, Inc. Cashflow Statement

Ask AI

Financial Statements

In millions of USD, except per-share amounts

	FY2013 12 months to Dec 31, 2013	FY2012 12 months to Dec 31, 2012	FY2011 12 months to Dec 31, 2011
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Amortization of deferred financing costs
Share based compensation expense
Changes in operating assets and liabilities:
Accounts receivable, net
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued expenses
Other long-term liabilities
Net cash used in operating activities
Cash flows from investing activities:
Purchases of property and equipment
Purchases of short-term investments
Purchases of investments
Proceeds from sale of investments
Net cash (used in) provided by investing activities
Proceeds from borrowing on long-term debt
Cash flows from financing activities:
Proceeds from borrowings on long-term debt
Repayments of long-term debt
Debt issuance costs
Proceeds from issuance of common stock
Net cash provided by financing activities
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents, beginning of the period
Cash and cash equivalents, end of the period
Supplemental Disclosure of Cash Flow Information:
Interest paid
Taxes paid

Comments